Nanjing Kechuang Pharmaceutical

Nanjing Kechuang Pharmaceutical Co., Ltd. is a China-based pharmaceutical company and a key manufacturing and R&D subsidiary of Jiangsu Kefeiping Pharmaceutical. The company focuses on the development and commercialization of small molecule therapeutics, particularly in the areas of gastroenterology, cardiovascular diseases, and respiratory disorders. Its lead commercial product is Vonoprazan acetate concentrated solution for injection, a potassium-competitive acid blocker (P-CAB) approved in China in 2026 for peptic ulcer hemorrhage. Nanjing Kechuang Pharmaceutical also advances a clinical-stage pipeline, including H029 for idiopathic pulmonary fibrosis and Amine ginkgolide B mesylate for cerebral ischemia, while maintaining state-of-the-art GMP manufacturing capabilities to support both internal programs and contract manufacturing services.